0001070081-18-000056.txt : 20180621
0001070081-18-000056.hdr.sgml : 20180621
20180621163304
ACCESSION NUMBER: 0001070081-18-000056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180619
FILED AS OF DATE: 20180621
DATE AS OF CHANGE: 20180621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Almstead Neil Gregory
CENTRAL INDEX KEY: 0001578850
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 18912142
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
wf-form4_152961316540176.xml
FORM 4
X0306
4
2018-06-19
0
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001578850
Almstead Neil Gregory
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
0
1
0
0
EVP Research Pharma Ops & Tech
Common Stock
2018-06-19
4
M
0
20000
10.85
A
37154
D
Common Stock
2018-06-19
4
S
0
8000
48.09
D
29154
D
Common Stock
2018-06-19
4
S
0
12000
48.46
D
17154
D
Common Stock
5125
I
By spouse
Stock Option (Right To Buy)
10.85
2018-06-19
4
M
0
20000
10.85
D
2023-05-15
Common Stock
20000.0
46898
D
Stock Option (Right To Buy)
451.2
2019-05-15
Common Stock
200.0
200
D
Stock Option (Right To Buy)
1149.6
2020-02-02
Common Stock
200.0
200
D
Stock Option (Right To Buy)
490.8
2021-04-27
Common Stock
216.0
216
D
Stock Option (Right To Buy)
218.4
2022-01-10
Common Stock
166.0
166
D
Stock Option (Right To Buy)
10.85
2023-05-15
Common Stock
3102.0
3102
D
Stock Option (Right To Buy)
27.05
2024-01-27
Common Stock
40000.0
40000
D
Stock Option (Right To Buy)
51.0
2025-01-01
Common Stock
69550.0
69550
D
Stock Option (Right To Buy)
30.86
2026-01-03
Common Stock
55000.0
55000
D
Stock Option (Right To Buy)
11.23
2027-01-02
Common Stock
35000.0
35000
D
Stock Option (Right To Buy)
18.01
2028-01-02
Common Stock
70000.0
70000
D
Stock Option (Right To Buy)
508.8
2019-10-07
Common Stock
12.0
12
I
By spouse
Stock Option (Right To Buy)
1149.6
2020-02-02
Common Stock
1.0
1
I
By spouse
Stock Option (Right To Buy)
490.8
2021-04-27
Common Stock
7.0
7
I
By spouse
Stock Option (Right To Buy)
218.4
2022-01-10
Common Stock
7.0
7
I
By spouse
Stock Option (Right To Buy)
27.05
2024-01-27
Common Stock
1300.0
1300
I
By spouse
Stock Option (Right To Buy)
51.0
2025-01-01
Common Stock
2060.0
2060
I
By spouse
The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.58 to $48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.38 to $48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Currently exercisable.
This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
/s/ Avraham S. Adler, attorney-in-fact
2018-06-21